Download MendeleyThe discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.
Yuan, C., St Jean, D.J., Liu, Q., Cai, L., Li, A., Han, N., Moniz, G., Askew, B., Hungate, R.W., Johansson, L., Tedenborg, L., Pyring, D., Williams, M., Hale, C., Chen, M., Cupples, R., Zhang, J., Jordan, S., Bartberger, M.D., Sun, Y., Emery, M., Wang, M., Fotsch, C.(2007) Bioorg Med Chem Lett 17: 6056-6061
- PubMed: 17919905
- DOI: https://doi.org/10.1016/j.bmcl.2007.09.070
- Primary Citation of Related Structures:
2RBE - PubMed Abstract:
A series of 2-anilinothiazolones were prepared as inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). The most potent compounds contained a 2-chloro or 2-fluoro group on the aniline ring with an isopropyl substituent on the 5-position of the thiazolone ring (compounds 2 and 3, respectively). The binding mode was determined through the X-ray co-crystal structure of the enzyme with compound 3. This compound was also approximately 70-fold selective over 11beta-HSD2 and was orally bioavailable in rat pharmacokinetic studies. However, compound 3 was >580-fold less active in the 11beta-HSD1 cell assay when tested in the presence of 3% human serum albumin.
Organizational Affiliation:
Amgen Inc., Thousand Oaks, CA 91320, USA.
